| Execution period | Valid up to April 29, 2027 |
|---|
NSE filing, NSE: JAYBEE. Summary written from the filing by ALFA Finder's alert engine.
Jay Bee Laminations Ltd: key numbers
- Share price
- ₹90.00
- Market cap
- ₹203.1 Cr
- Revenue (annual)
- ₹548.0 Cr
- Net profit (annual)
- ₹18.26 Cr
- P/E (TTM)
- 11.1×Sector 50.9×
- Promoter holding
- 70.61%
- FII holding
- 0.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jay Bee Laminations Ltd
All →Jay Bee Laminations Annual General Meeting
Jay Bee Laminations held its 38th AGM on September 26, 2026, via video conferencing. Shareholders transacted ordinary and special business, including borrowing and charge approvals.
Jay Bee Laminations Annual General Meeting
Jay Bee Laminations Limited has scheduled its 38th Annual General Meeting for September 26, 2026, to transact ordinary and special business, including borrowing power approvals.
Jay Bee Laminations Board Meeting Outcome
Jay Bee Laminations Limited's board approved the appointment of secretarial, internal, and cost auditors for FY 2026-27. It also approved the notice for its 38th AGM.
Jay Bee Laminations Management Change
Mr. Atul Ladha resigned as Independent Director of Jay Bee Laminations. The resignation is effective from June 26, 2026.
Jay Bee Laminations Management Change
Jay Bee Laminations redesigned Mrs. Sunita Aggarwal from Executive Director to Non-Executive Non-Independent Director. Effective May 26, 2026, the move adjusts the board's leadership structure.
Jay Bee Laminations Board Meeting Outcome
Jay Bee Laminations approved redesignating Mrs. Sunita Aggarwal from Executive to Non-Executive Non-Independent Director. The change aligns with her evolving strategic guidance and advisory role.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.